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Abstract Genotype-based diagnostics for antibiotic resistance represent a promising alternative
to empiric therapy, reducing inappropriate antibiotic use. However, because such assays infer
resistance based on known genetic markers, their utility will wane with the emergence of novel
resistance. Maintenance of these diagnostics will therefore require surveillance to ensure early
detection of novel resistance variants, but efficient strategies to do so remain undefined. We
evaluate the efficiency of targeted sampling approaches informed by patient and pathogen
characteristics in detecting antibiotic resistance and diagnostic escape variants in Neisseria
gonorrhoeae, a pathogen associated with a high burden of disease and antibiotic resistance and
the development of genotype-based diagnostics. We show that patient characteristic-informed
sampling is not a reliable strategy for efficient variant detection. In contrast, sampling informed by
pathogen characteristics, such as genomic diversity and genomic background, is significantly more
efficient than random sampling in identifying genetic variants associated with resistance and
diagnostic escape.
Introduction
Nucleic acid-based diagnostics that enable rapid pathogen identification and prediction of drug sus-
ceptibility profiles can improve clinical decision-making, reduce inappropriate antibiotic use, and
help address the challenge of antibiotic resistance (McAdams et al., 2019; Fingerhuth et al., 2017;
Tuite et al., 2017). However, the sensitivity of such diagnostics may be undermined by undetected
genetic variants (Andre´ et al., 2017; Berhane et al., 2018; Herrmann et al., 2008;
Guglielmino et al., 2019; Whiley et al., 2011; Golparian et al., 2012; Bruisten et al., 2004;
Lee et al., 2018a; Marks et al., 2018). Pathogen surveillance programs aimed at early detection of
novel variants are crucial to ensuring the clinical utility and sustainability of these diagnostics.
Use of traditional nucleic acid amplification tests (NAATs) for pathogen identification and geno-
type-based diagnostics for antibiotic resistance can select for genetic variants that escape detection
(Smid et al., 2019). Mutations and/or deletions at the NAAT target locus that cause an amplification
failure have arisen in Neisseria gonorrhoeae, Chlamydia trachomatis, Staphylococcus aureus, and
Plasmodium falciparum, resulting in false negative diagnostic errors only detected when using
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another diagnostic platform (Berhane et al., 2018; Herrmann et al., 2008; Guglielmino et al.,
2019; Lee et al., 2018a). Diagnostic escape associated with genotype-based diagnostics for antibi-
otic resistance are the result of resistance-conferring variants (e.g., mutations or accessory genes)
not accounted for in the diagnostic’s panel of resistance markers (Andre´ et al., 2017) and require
phenotypic testing to be uncovered.
We recently presented a framework to quantify the sampling rate for early detection of novel
antibiotic resistance variants, defining the number of isolates that would need to undergo confirma-
tory phenotyping from those predicted by genotype to be susceptible (Hicks et al., 2019). Underly-
ing this model are assumptions of unbiased sampling across a population and independence among
all isolates. However, these assumptions may not hold in practice, as some subsets of the population
(e.g., demographics and/or geographic regions) may be more likely to be sampled than others, and
clonal transmission may result in repeated sampling of closely related isolates (Rempel and Laup-
land, 2009; Unemo et al., 2019; Hutinel et al., 2019; Van Goethem et al., 2019). The real-world
application of this model may also be challenging for pathogens with high case incidence, such as N.
gonorrhoeae, as the cost of phenotyping required by this model for timely detection of novel resis-
tance variants is likely to be high (Hicks et al., 2019).
Implementing a practical surveillance system thus requires improving efficiency over unbiased
testing by prioritizing samples in which novel diagnostic escape variants are most likely to be found.
There are numerous hypotheses for how to focus sampling and most quickly identify these variants.
Novel variants may be more likely to emerge or spread in certain anatomical niches, demographics,
or geographic regions (Lewis, 2013; Collignon et al., 2018; Frost et al., 2019; Hernando Rovirola
et al., 2020), some of which may be systematically under-sampled (Kirkcaldy et al., 2019) and thus
may provide a basis for sampling priority. Data on such characteristics may be obtained from meta-
data recorded during clinical encounters. Alternatively, they may be inferred from pathogen geno-
mic data. Isolates or clades that are genetically divergent from the majority of isolates in a
population may reflect travelers, their contacts, or otherwise under-sampled lineages (Perrin et al.,
2003; Pham Thanh et al., 2016; Kingsley et al., 2009; Mac Aoga´in et al., 2016). Some pathogen
genomic backgrounds may be more conducive to the evolution of novel resistance mechanisms
(Borrell and Gagneux, 2011), and markers of these genomic backgrounds (e.g., variants associated
with a range of resistance mechanisms and/or resistance to other drugs) may help improve sampling
efficiency. Similarly, given historical patterns of antibiotic use, novel resistance may emerge on a
background of existing resistance (Gould and MacKenzie, 2002). Thus, genetic markers of resis-
tance to certain drugs may facilitate identification of lineages more likely to have experienced selec-
tive pressures leading to emergence of novel resistance variants.
Here, we test the performance of sampling strategies informed by these hypotheses using N.
gonorrhoeae surveillance data. N. gonorrhoeae offers a useful model, given the increasing drug
resistance and recent focus on developing sequence-based resistance diagnostics
(Fingerhuth et al., 2017; Hook and Kirkcaldy, 2018). We present targeted sampling approaches
informed by patient (i.e., demographics, anatomical site of isolate collection, geographical region,
recent travel history, or sex worker status) and pathogen (i.e., phylogenetic or genomic background)
information. We assess the efficiency of each of these strategies to detect rare (<10% prevalence)
resistance variants associated with current or recent first-line recommended antibiotics (i.e., azithro-
mycin [AZM] and extended spectrum cephalosporins [ESCs]), as well as rare genetic variants associ-
ated with diagnostic escape, across five genomic surveys with various demographic, geographic,
and temporal ranges. We show that phylogeny- and genomic background-aware sampling
approaches can increase the detection efficiency of known variants over random sampling, whereas
patient feature-based sampling approaches do not. Our results suggest that implementation of such
targeted sampling approaches into surveillance programs may reduce the number of cases of novel
resistance that occur before it is detected, as well as the resources required to undertake surveil-
lance, compared to random sampling of a population.
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Results
Composition of the datasets
The datasets (Table 1) were biased across patient demographics and/or geographic regions
(Supplementary files 1 and 2A). Isolates from men and men who have sex with men (MSM) were
overrepresented in datasets 1 and 2 compared to overall gonorrhea incidence in men and MSM in
the US and Australia, respectively, during the study periods (Supplementary file 2A, p<0.001 for
both datasets by chi-squared test of men vs. women and MSM vs. non-MSM in dataset vs. reported
incidence). Dataset 4 was comprised exclusively of isolates from men (Yahara et al., 2018). While it
is difficult to estimate the prevalence of pharyngeal gonococcal infections, as they tend to be asymp-
tomatic (Wiesner et al., 1973), pharyngeal isolates represented 4% and 18% of isolates with
reported anatomical site of collection in datasets 1 and 2, respectively. This suggests either sampling
bias across anatomical sites in at least one of the datasets or substantial variation across the two
study populations in prevalence of pharyngeal gonococcal infections. Similarly, the geographic distri-
bution of isolates in dataset 3 was significantly different from the reported case incidence across
countries (Supplementary file 2A, p<0.001 by chi-squared test of prevalence for each of the coun-
tries in dataset 3 vs. the reported overall incidence for each of the countries).
Targeted sampling based on patient characteristics
We investigated whether sampling evenly across demographic groups (demography-aware sam-
pling), anatomical sites of isolate collection (niche-aware sampling), and geographic regions (geogra-
phy-aware sampling) increased detection efficiency of resistance variants by ameliorating some of
the demographic, niche, or geographic sampling biases. We further investigated whether preferen-
tially sampling patients with recent overseas sexual encounters or recent sex work, two characteris-
tics hypothesized to be associated with the introduction and/or increased transmission of resistance
(Lewis, 2013; Frost et al., 2019; Hernando Rovirola et al., 2020), increased the detection effi-
ciency of resistance variants. To do so, we simulated and compared the detection efficiency of three
genetic resistance variants (Table 2) using each of these targeted sampling strategies and random
sampling.
The detection efficiency was not improved by demography-, niche-, geography-aware sampling
compared to random sampling for any of the resistance variants (Supplementary file 2B, Figure 1).
In several cases, detection efficiency significantly decreased in demography- or geography-aware
sampling compared to random sampling, reflecting enrichment of the resistance variant in the over-
represented demographic or geographic region. However, no significant association between a
given resistance variant and demographic group was observed across both dataset 1 and dataset 2,
and no demographics or geographic regions were significantly enriched for all variants
(Supplementary file 1), suggesting that preferential sampling of any of these demographics or geo-
graphic regions would not be a reliable strategy for increasing novel variant detection efficiency. For
example, while penA XXXIV was significantly enriched in MSM compared to men who have sex with
women and women who have sex with men (MSW/WSM) in dataset 2 (p<0.003, Fisher’s exact test),
there was no significant difference in the proportions of MSM and MSW/WSM with penA XXXIV in
Table 1. Summary of datasets.
Dataset
Temporal
range Nisolates
Geographic
range Metadata available SRA study ID/Reference
1 2011–2015 896 New York, NY,
US
Gender, sexual behavior, anatomical site of isolation ERP011192 (Mortimer et al.,
2020)
2 2016–2017 2186 Victoria,
Australia
Gender, sexual behavior, anatomical site of isolation, travel history,
sex worker status
SRP185594 (Williamson et al.,
2019)
3 2013 1054 Europe Country of sample collection ERP010312 (Harris et al.,
2018)
4 2015 244 Japan Prefecture of sample collection DRP004052 (Yahara et al.,
2018)
5 2014–2015 398 New Zealand N/A SRP111927 (Lee et al., 2018b)
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dataset 1 (p=0.461, Fisher’s exact test). Similarly, while the AZM-R-associated RplD G70D mutation
in dataset 3 was at highest prevalence in patients from Malta and Greece (10% and 6.25%, respec-
tively) and absent from patients from Denmark, the AZM-R-associated 23S C2611T variant was at
highest prevalence in patients from Denmark (5.45%) and absent from patients from Malta or
Greece.
Isolates from patients with recent overseas sex were associated with significantly longer terminal
branches compared to patients that had only engaged in sex locally (Figure 1—figure supplement
1), in support of the hypothesis that international travel may be associated with the importation of
novel or divergent strains, or, more generally, that isolates from travelers may be more likely to be
associated with under-sampled lineages. Preferentially sampling from patients with recent overseas
sex significantly improved detection efficiency of the RplD G70D mutation and the penA XXXIV
allele, as these were at marginally higher prevalence in isolates from patients with recent overseas
sex compared to those from patients who had only engaged in sex locally (3.03% overseas vs. 0.98%
local and 2.02% overseas vs. 1.67% local, respectively, p=0.090 and 0.683, respectively, by Fisher’s
exact test for both variants). In contrast, the 23S C2611T mutation was exclusively present in isolates
from patients who had engaged in sex locally (Supplementary files 1 and 2C). Similarly, while the
23S C2611T mutation was marginally enriched in isolates from patients who had engaged in recent
sex work compared to patients who had not (2.33% in sex workers vs. 1.31% in non-sex workers,
p=0.327 by Fisher’s exact test), and thus preferentially sampling from sex workers significantly
improved detection efficiency of this variant compared to sampling from the full patient population,
detection efficiencies for the RplD G70D mutation and the penA XXXIV allele were not significantly
improved by preferentially sampling from sex workers (Supplementary files 1 and 2 C).
Together, these results suggest that while targeted sampling based on patient characteristics
may increase detection efficiency of some novel variants, it is difficult to predict which groups to tar-
get for all potential novel variants.
Targeted sampling based on genetic diversity
To assess whether preferential sampling of lineages that are divergent from those that have been
previously sampled may increase detection efficiency of genetic resistance variants over random
sampling, we simulated phylogeny-aware sampling using two methods: 1) maximization of the phylo-
genetic distance covered with each isolate sampled (distance maximization) and 2) even sampling
across phylogenetic lineages (clonal group).
Table 2. Summary by dataset of the prevalence and distribution of the genetic markers of resistance and resistance phenotypes
tested.
Variant
Genetic Phenotypic
RplD G70D
23S rRNA C2611T (2–4
alleles) penA XXXIV
CRO-RS (0.12
mg/mL)
CFX-R (>0.25 mg/
mL)
Drug AZM (Grad et al.,
2016)
AZM (Lk et al., 2002) ESCs (Grad et al.,
2014)
N/A N/A
Prevalence of variant in dataset 1 10.04%* 0.11% 5.25% 1.47% 0.11%
2 1.14% 1.24% 1.69% 0% 0%
3 2.47% 0.95% 15.68%* 1.04% 0.76%
4 11.07%* 1.23% 0.41% 6.56% 8.20%
5 0.75% 0.50% 2.26% 0.25% 0%
Phylogenetic D statistic for variant in
dataset
1  0.18 17.50  0.29 N/A N/A
2  0.10 0.46  0.24 N/A N/A
3 0.05 0.30  0.20 N/A N/A
4  0.16 1.83 1.81 N/A N/A
5 0.83 1.12  0.15 N/A N/A
*Given the >10% prevalence of RplD G70D in datasets 1 and 4 and penA XXXIV in dataset 3, these variants were excluded from sampling simulations.
AZM, azithromycin; ESC, extended-spectrum cephalosporin; CRO-RS, ceftriaxone reduced susceptibility; CFX-R, cefixime resistance.
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Figure 1. The impact of demography-, niche-, and geography-aware sampling on the detection efficiency of genetic resistance variants. Dot plots
showing the detection efficiency (with lines indicating the mean and 95% confidence intervals from 100 simulations) for resistance variants RplD G70D
(A–B), 23S rRNA C2611T (C–D), and penA XXXIV (E–F) in datasets 1 and 2. In datasets 1 and 2, targeted sampling was informed by demographic
(gender and sexual behavior) and anatomical site of isolate collection (niche) information (A, C, and E), and in datasets 3 and 4, targeted sampling was
informed by country or prefecture of sample collection (B, D, and F). Dot colors indicate the sampling approach, and asterisks indicate a significant
difference (p<0.05 by Mann-Whitney U test) in detection efficiency between the demography-, niche- or geography-aware approach compared to
random sampling (*p<0.05, **p<0.01, ***p<0.001; red asterisks indicate significantly lower detection efficiency of demography- or geography-aware
approaches compared to random sampling). Note that sampling simulations were not performed for RplD G70D in datasets 1 and 4 or for penA XXXIV
in dataset 3 as prevalence of the variants in these datasets was >10%. n.s., not significant at a = 0.05; M, men; W, women; MSM, men who have sex
with men; MSW, men who have sex with women; WSM, women who have sex with men.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Isolates from patients with travel-associated gonorrhea are associated with longer terminal branches compared to patients with
locally-acquired gonorrhea.
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While the distance maximization approach increased detection efficiency compared to random
sampling for some variants, there were numerous instances in which this approach, which led to pref-
erential sampling of isolates associated with long branches, substantially decreased detection effi-
ciency (Figure 2, Supplementary file 2D).
The clonal group sampling approach prevents repeated sampling of very closely related isolates
until all unique phylogenetic clusters have been sampled. Thus, for both rare variants that are clon-
ally distributed and rare variants that are more randomly dispersed throughout the phylogeny (e.g.,
penA XXXIV and 23S rRNA C2611T mutations, respectively, Table 2), this approach increases detec-
tion efficiency in cases where 1) there is substantial clonality among isolates and 2) a substantial pro-
portion of variant-positive isolates do not occur in clonal lineages dominated by variant-negative
isolates (Figure 2E). In such datasets, effectively collapsing large variant-negative lineages into a sin-
gle representative increases the effective prevalence of the variants and thus the detection efficiency
of the clonal group approach compared to random sampling. The clonal group sampling approach
significantly decreased detection efficiency in only one instance (i.e., the 23S rRNA C2611T variant in
dataset 4, Supplementary file 2D), where all isolates with the variant appeared in large clonal line-
ages of predominately variant-negative isolates (Figure 2D).
In cases where the clonal group sampling approach did not perform better than random sam-
pling, adjusting the threshold for clonal grouping and/or a marginal increase in the prevalence of
variant-positive isolates could elevate the relative performance of this targeted approach. We chose
134 SNPs as an example threshold for clonal grouping, as it represents the lower 95% confidence
interval of the mean of SNP distances between each CFX-R resistant and the closest susceptible iso-
late in datasets 1–5 (see Methods). In the case of the 23S rRNA C2611T variant in dataset 4, the
average prevalence of the variant across clonal groups (i.e., the total number of variant-positive iso-
lates, counting each variant-positive isolate as [1 / [1 + the total number of additional isolates that
are 134 SNPs of the isolate]], divided by the number of clonal groups) is 0.005, lower than the
actual prevalence of 0.012. However, if the threshold for clonal grouping was lower in this instance
(e.g., 50 SNPs), the effective prevalence of the variants would be 0.020, greater than the actual prev-
alence of 0.012. Similarly, using the 134 SNP threshold, if one additional isolate that was >134 SNPs
from any other isolates in this dataset had the 23S rRNA C2611T mutation, the average prevalence
of the variant across clonal groups would be 0.036, greater than the actual prevalence of 0.016, and
thus the clonal group approach would outperform random sampling.
To further assess the performance of phylogeny-aware sampling in the context of rare genetic
variants that may have emerged in response to diagnostic pressure, we simulated random and phy-
logeny-aware sampling to assess detection efficiency of an additional set of variants. Specifically, we
assessed a panel of N. gonorrhoeae diagnostic escape variants: the 16S rRNA C1209A mutation, the
N. meningitidis-like porA, and the cppB deletion, all of which have been previously associated with
diagnostic failure (Guglielmino et al., 2019; Whiley et al., 2011; Golparian et al., 2012;
Bruisten et al., 2004) and were present in one or more of datasets 1–5 at low prevalence (Table 3).
The G168A mutation in the primer binding region of DR-9A, the target of the COBAS 4800 CT/NG
(Roche) diagnostic, has not previously been documented but was present in 0.1% of strains from
dataset 2. All of the diagnostic-associated variants assessed appeared in divergent backgrounds and
were thus detected more efficiently by phylogeny-aware sampling compared to random sampling
(Figure 2F–I, Supplementary file 2E). Like the results from the simulations based on resistance var-
iants, the distance maximization approach maximized detection efficiency for some of the diagnos-
tic-associated variants, but superiority of this approach to random sampling was not consistent
across all variants. However, the clonal group approach performed significantly better than random
sampling for all diagnostic-associated variants across all datasets.
The relative performance of the clonal group sampling approach compared to random sampling
was generally consistent across multiple thresholds based on pseudogenomes (i.e.,134
SNPs, 422 SNPs, and fastBAPS groups); relative performance of clonal group sampling using
MLSTs, however, was less consistent and was significantly worse than random sampling for several
variants (Figure 2—figure supplement 1, Supplementary file 2D-E). Together, these results sug-
gest that preferentially sampling isolates that, based on whole genome sequencing (WGS), are phy-
logenetically divergent from those that have previously been sampled may increase detection
efficiency of novel resistance variants.
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Figure 2. The impact of phylogeny-aware sampling on the detection efficiency of genetic resistance and diagnostic escape variants. Scatter dot plots
showing the detection efficiency (with lines indicating the mean and 95% confidence intervals from 100 simulations) for resistance variants RplD G70D
(A), 23S rRNA C2611T (B), and penA XXXIV (C) in datasets 1–5. Note that sampling simulations were not performed for RplD G70D in datasets 1 and 4
or for penA XXXIV in dataset 3 as prevalence of the variants in these datasets was >10%. Maximum-likelihood phylogenies produced from
Figure 2 continued on next page
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Targeted sampling based on genetic markers
Multiple drug resistance is more common in pathogenic bacteria than one would expect from the
product of frequencies of resistance to individual drugs (Chang et al., 2015; Lehtinen et al., 2019).
This suggests that novel resistance mechanisms might be more likely to arise and spread in bacterial
strains that are already resistant to other drugs, a phenomenon that has been documented in N.
gonorrhoeae (Goldstein et al., 2012). It may therefore be fruitful to look for novel resistance var-
iants for one drug in genetic backgrounds that are resistant to other drugs. It may be similarly effec-
tive to sample preferentially isolates with genetic markers that have been associated with a range of
resistance mechanisms (e.g., through epistatic interactions with other genetic variants) within and/or
across different antibiotics when screening for a novel resistance variant. For example, as ciprofloxa-
cin was the recommended first-line therapy for uncomplicated gonorrhea through 2005 in the United
Kingdom (Whittles et al., 2018), 2007 in the United States (Centers for Disease Control and Pre-
vention (CDC), 2007), and more recent years in other countries (Hemarajata et al., 2016;
Unemo and Dillon, 2014; Bazzo et al., 2018), we investigated whether resistance to ESCs is signifi-
cantly more likely to occur in the background of genotypic ciprofloxacin resistance (i.e., in strains
with the GyrA S91F mutation). Similarly, as mutations at positions 120 and/or 121 in PorB, the major
outer membrane protein in gonococci, have been associated with resistance to a range of drugs
from multiple classes (Mortimer and Grad, 2019), we investigated whether resistance to ESCs is sig-
nificantly more likely to occur in strains with PorB 120 and/or 121 mutations. Isolates with CRO-RS
and CFX-R were significantly more likely to have the GyrA S91F mutation and the PorB G120 and/or
A121 mutations than the wild-type GyrA S91 or wild-type PorB G120/A121 (p<0.001, Fisher’s exact
test, Figure 3A–B). Further, both GyrA S91F and PorB G120 and/or A121 mutations occurred across
a range of ESC resistance locus haplotypes (Figure 3C–D). For all datasets with CRO-RS or CFX-R
isolates, detection efficiency of both variants was significantly increased by only sampling isolates
with the GyrA S91F mutation or the PorB G120 and/or A121 mutations (Figure 3E–F,
Supplementary file 2F). Together, these results suggest that preferential sampling of isolates with
certain genetic markers, including markers of resistance to previous first-line antibiotics, may
increase the detection efficiency of novel resistance variants.
Figure 2 continued
pseudogenome alignments (with predicted regions of recombination removed) of isolates from dataset 4 (D) and dataset 2 (E). Presence or absence of
the 23S rRNA C2611T mutation (in at least 2/4 alleles) and the mosaic penA XXXIV allele is indicated by colored rings. Scatter dot plots showing the
detection efficiency (with lines indicating the mean and 95% confidence intervals from 100 simulations) for diagnostic-associated variants 16S rRNA
C1209A (F), N. meningitidis-like porA (G), cppB deletion (H), and DR-9A G168A (I) in all datasets in which the variant was present. Dot colors in A–C)
and F–I) indicate the sampling approach, and asterisks indicate a significant difference (p<0.05 by Mann-Whitney U test) in detection efficiency between
the phylogeny-aware approach compared to random sampling (*p<0.05, **p<0.01, ***p<0.001; red asterisks indicate significantly lower detection
efficiency of the phylogeny-aware approach compared to random sampling, and green asterisks indicate significantly higher detection efficiency of the
phylogeny-aware approach compared to random sampling). n.s., not significant at a = 0.05.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Detection efficiency of clonal group sampling across different similarity thresholds.
Table 3. Summary of the potential diagnostic escape variants assessed.
Variant Diagnostic assay Documented association with diagnostic failure
Prevalence in dataset
1 2 3 4 5
16S rRNA C1209A (four alleles) Aptima GC Combo Yes
(Guglielmino et al., 2019)
0.11% 0.09% 0% 0% 0%
N. meningitidis-like porA In-house
(Whiley et al., 2004;
Whiley et al., 2005)
Yes
(Whiley et al., 2011;
Golparian et al., 2012)
0.11% 0.05% 0% 0% 0%
cppB deletion In-house (Diemert et al., 2002;
Van Dyck et al., 2001)
Yes
(Bruisten et al., 2004)
1.12% 0.05% 0.47% 0% 7.29%
DR-9A G168A Roche COBAS 4800 CT/NG No 0% 0.09% 0% 0% 0%
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Figure 3. The impact of genomic background-aware sampling on the detection efficiency of phenotypic resistance variants. Bar charts showing the
proportions of ceftriaxone reduced susceptibility (CRO-RS) isolates, ceftriaxone susceptible (CRO-S) isolates, cefixime resistant (CFX-R) isolates, and
cefixime susceptible (CFX-S) isolates with GyrA S91F and GyrA S91 wild-type alleles (A) and with PorB G120 and/or A121 mutations and PorB G120 and
A121 wild-type alleles (B) across datasets 1–5. Bar charts showing the number of (C) CRO-RS and (D) CFX-R isolates with each haplotype, along with
heatmaps showing the presence or absence of the GyrA S19F mutation, the PorB G120 and/or A121 mutations, and other alleles at loci previously
associated with extended spectrum cephalosporin resistance. Bar colors in (C) and (D) indicate the dataset from which the isolates were derived. Scatter
dot plots showing the detection efficiency (with lines indicating the mean and 95% confidence intervals from 100 simulations) for CRO-RS (E) and CFX-R
(F) in all datasets in which the variant was present. Dot colors in E–F) indicate the sampling approach, and asterisks indicate a significant difference
Figure 3 continued on next page
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Discussion
With sequencing becoming more integral to routine pathogen surveillance and diagnostics, it is
important to ensure that models mapping genotypic information to expected pathogen phenotype
and/or clinical outcome are comprehensive and current (Dona` et al., 2017). In the case of genotype-
based diagnostics, sustained phenotypic surveillance is crucial for identifying resistance variants that
have recently emerged and/or increased in prevalence from previously undetected levels. While
effective incorporation of patient metadata into surveillance strategies may be challenging, availabil-
ity and incorporation of information on pathogen characteristics (e.g., pathogen genomic data) into
surveillance programs may ultimately decrease the cost of surveillance to maintain the sensitivity of
these diagnostic tools.
Collection of patient metadata, including demographic and geographic information, is crucial to
understanding the epidemiology of drug resistance. However, it may be difficult to obtain data on
the relevant patient features, and the predictive power of such features may rapidly decay because
of patient mobility and interactions (Goldstein et al., 2017). While availability of patient metadata
varied across the datasets assessed, our results suggest that while incorporation of patient metadata
into sampling strategies may increase detection efficiency for some novel resistance variants, it may
be difficult to generalize for all potential novel resistance variants. It is possible that targeted sam-
pling based on patient characteristics may be more reliable in the context of pathogens, antibiotic,
and/or patient characteristics not assessed here.
Incorporation of WGS into routine pathogen surveillance by public health agencies
(European Centre for Disease Prevention and Control, 2019; Brown et al., 2019) may facilitate
use of genomic information in phenotypic sampling strategies, particularly with emerging metage-
nomic approaches that do not require bacterial culture (Brˇinda et al., 2020). Our results show that
phylogeny-aware sampling, particularly the clonal group approach, which reduces the amount of
repeated sampling of closely related isolates, significantly improved detection efficiency over ran-
dom sampling for multiple resistance and diagnostic-associated variants. Further, identification of
and preferential sampling of isolates with genetic markers that are consistently predictive of resis-
tance across a range of mechanisms, including those associated with resistance to other drugs, may
supplement phylogeny-aware sampling to further optimize detection efficiency of novel variants.
However, the utility of sampling based on genetic markers of other resistance mechanisms will likely
vary substantially across different drugs and be influenced by future treatment guidelines.
While the clonal group sampling approach increased detection efficiency for the resistance and
diagnostic escape variants assessed here, it may be difficult to determine the most effective and reli-
able metric or threshold for clonal grouping, especially as this is likely to vary across different clinical
populations, antibiotics, and bacterial species. Detection efficiency was generally consistent across
the two SNP thresholds and fastBAPS groupings based on WGS. However, performance of the
clonal group approach using MLSTs was inconsistent and, in some instances, worse than random
sampling, likely due to the shortcomings of MLST compared to WGS-based approaches in distin-
guishing between AMR variant-positive clades and more distantly-related variant-negative clades in
species such as N. gonorrhoeae (Harris et al., 2018). This suggests that this approach is sensitive to
similarity thresholds and that a low SNP threshold based on WGS assemblies may be the most
appropriate approach, particularly in a population where there is expected to be substantial clonality
among isolates and thus, even with a low threshold, detection efficiency will be improved by the
clonal group approach. More broadly, surveillance incorporating WGS rather than MLST loci alone
may further promote NAAT sustainability by enabling screening for variants with previously unde-
tected mutations in target loci, such as the N. gonorrhoeae DR-9A G168A variants, that may be
associated with diagnostic escape. While sequencing errors may occasionally impair clonal grouping
of closely related isolates, thus weakening the benefit of the clonal group approach relative to
Figure 3 continued
(p<0.05 by Mann-Whitney U test) in detection efficiency between the phylogeny-aware approach compared to random sampling (*p<0.05, **p<0.01,
***p<0.001; green asterisks indicate significantly higher detection efficiency of the genomic background-aware approach compared to random
sampling).
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random sampling, we expect the impact of such errors to be marginal in the absence of large
sequence quality issues. Such large quality issues should be apparent at the first stages of an
analysis.
We have assessed these targeted sampling approaches in detection of multiple resistance var-
iants across a range of populations, but these represent only a fraction of resistance mechanisms in a
single species. These findings may extend to other antibiotics and bacterial species. For example,
given the high degree of clonality among M. tuberculosis isolates and the significant variation in
prevalence of drug resistance and resistance-conferring genotypes across clonal groups
(Merker et al., 2015; Casali et al., 2014), the clonal group sampling approach may similarly improve
detection efficiency of novel resistance variants in M. tuberculosis. For species in which drug resis-
tance is primarily acquired through gene acquisition, it is unclear if phylogeny-aware sampling based
on the core genome will improve detection efficiency of novel variants, though in gonococcus, there
is evidence of a relationship between the core genome and the plasmid-borne resistance genes bla-
TEM and tetM (Sa´nchez-Buso´ et al., 2019), and it is further possible that, combined with core
genome-based phylogeny-informed sampling, screening for homologs of known resistance genes
from other species may expedite identification of any novel resistance genes acquired by the species
of interest. However, in addition to providing a more practically applicable (i.e., less computationally
intensive) alternative to phylogeny-informed sampling, sampling informed by k-mer distances
(Ondov et al., 2016; Lees et al., 2019) may also be more generalizable to a broader range of novel
resistance mechanisms. Further, the requirement of confirmatory phenotyping to identify novel resis-
tance may not extend to pathogens that are expected to be associated with reliably-identifiable
treatment failures, as for these pathogens, identification of treatment failure likely represents the
most efficient method of novel resistance variant detection (Berenger et al., 2019). However, for
other pathogens, such as N. gonorrhoeae (Eyre et al., 2018), treatment failures may go undetected
for reasons including partial abatement of symptoms or long treatment regimens. Ultimately, as
genotype-based diagnostics for antibiotic resistance become available for more species, it will be
important to assess the efficiencies of these approaches across pathogens with different clinical, epi-
demiological, and evolutionary paradigms.
Since we lack the datasets to assess targeted sampling of variants from the time they first
emerged in a population, any associations we observed between the variants and patient or patho-
gen features do not necessarily reflect those around the time of emergence. Thus, more longitudinal
epidemiological and genomic studies, particularly after the implementation of genotype-based diag-
nostics, are necessary to better characterize patterns of novel resistance emergence and inform tar-
geted surveillance approaches.
The phylogeny-aware sampling approaches presented here are based on the assumption that
genomic data will be available for the pool of potential isolates from incident cases that may
undergo confirmatory phenotyping. However, using information on isolate features to increase sur-
veillance efficiency may be feasible even in the absence of mass prospective sequencing. For exam-
ple, under the general assumption that novel resistance variants are more likely to appear in
underrepresented lineages, phylogeny-aware surveillance could be paired with a diagnostic
approach such as genomic neighbor typing (Brˇinda et al., 2020), where any isolates with either sus-
ceptible or low confidence calls that appear to be divergent from the genomes in the reference
database would be prioritized for confirmatory phenotyping. Similarly, a diagnostic that predicts
AMR phenotypes through a combination of transcriptomic and genomic typing
(Bhattacharyya et al., 2019) may facilitate targeted surveillance by identifying isolates with ambigu-
ous predictions (e.g., isolates with transcriptional signatures of resistance that lack known genomic
markers of resistance) that could be prioritized for confirmatory phenotyping.
While the focus of this study was to introduce and evaluate approaches to increase the efficiency
of surveillance programs for maintaining marker-based AMR diagnostics, these approaches may be
broadly applicable to surveillance programs aimed at tracking AMR in general and/or other pheno-
types of interest that may be time- and/or resource-intensive to directly measure. For example, pro-
grams such as the National Antimicrobial Resistance Monitoring System for Enteric Bacteria (https://
www.cdc.gov/narms/) could adopt these targeted sampling approaches to prioritize isolates for phe-
notypic testing.
Advances in diagnostics, extensive sequencing of clinical isolates, and large collections of clinical
and pathogen data together provide new opportunities for integrating data streams and optimizing
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surveillance efforts. As marker-based point-of-care AMR diagnostics are developed and imple-
mented, optimization of surveillance systems will require assessments like those modeled here of
species-, drug-, and population-specific factors that may affect the emergence and distribution of
diagnostic escape resistance variants, as well as how the diagnostic itself may complement surveil-
lance efforts.
Materials and methods
Dataset preparation and phylogenetic reconstruction
See Table 1 for details of the N. gonorrhoeae datasets and Tables 2 and 3 for the variants assessed.
Raw sequencing data were downloaded from the NCBI Sequence Read Archive. Genomes were
assembled using SPAdes v3.13 (Bankevich et al., 2012) with default parameters and the careful
option to minimize the number of mismatches. Assembly quality was assessed using QUAST v4.3
(Gurevich et al., 2013), and contigs < 500 bp in length and/or with <10 x average coverage were
removed. Isolate reference-based pseudogenomes were constructed by mapping raw reads to the
NCCP11945 reference genome (RefSeq accession number NC_011035.1) using BWA-MEM v7.12
(Li, 2013), the Picard toolkit v2.8 (Picard development team, 2016) to identify duplicate reads, and
Pilon v1.22 (Walker et al., 2014) to determine the base call for each site, with a minimum depth of
10 and a minimum base quality of 20.
Loci in Tables 2 and 3 were extracted from the genome assemblies using blastn (Altschul et al.,
1990) followed by MUSCLE alignment using default parameters (Edgar, 2004) to assess the pres-
ence or absence of the resistance variants. Presence or absence of mutations in the multi-copy 16S
and 23S rRNA genes and the repetitive DR-9A and DR-9B regions (Dailey et al., 2013) was assessed
using BWA-MEM, the Picard toolkit, and Pilon, as above, to map raw reads to a single 16S rRNA
allele, a single 23S rRNA allele, a single DR-9A region, and a single DR-9B region from the
NCCP11945 reference isolate and determine the mapping quality-weighted percentage of each
nucleotide at the site of interest. See Table 4 for information on the reference sequences used for
variant calling. Isolate metadata and resistance variant profiles are given in Supplementary file 1.
Sampling bias across demographic and geographic groups was assessed by comparing (by chi-
squared test) reported gonorrhea incidence across the groups in the population from which the
dataset samples were collected to the prevalence of the groups in each dataset. Association
between genetic variants and demographic or geographic groups and between phenotypic resis-
tance variants and genetic markers in each of datasets was assessed by Fisher’s exact test, due to
the low prevalence of the variants.
Gubbins v2.3.4 (Croucher et al., 2015) was used with default parameters to identify and mask
recombinant regions from the pseudogenomes and build maximum likelihood phylogenies from the
Table 4. Reference information for the genetic variants assessed.
Variant Reference accession Coordinates of genetic locus in reference entry Position of mutation in reference locus
RplD G70D NC_011035.1 2033052–2033672 amino acid 70
23S rRNA
C2611T
NC_011035.1 1263408–1266305 nucleotide 2603
penA XXXIV NZ_LT906440.1 1588456–1590201 N/A (assessed presence/
absence of this allele)
16S rRNA
C1209A
NC_011035.1 1266903–1268450 nucleotide 1192
N. meningitidis-
like porA
NC_011035.1 735796–737125 N/A (assessed nucleotide similarity across
the full locus with a threshold of  90%)*
cppB deletion LT592149.1 2912–3553 N/A (assessed presence/absence of full locus)
DR-9A G168A NC_011035.1 530088–530277 nucleotide 168
*Isolates with a porA pseudogene with 90% similarity to the NC_011035.1 porA pseudogene were called positive for N. meningitidis-like porA. Note that
all such isolates were confirmed to have a porA pseudogene that was 92% similar to the N. meningitidis porA (GenBank Accession: GQ173789.1), while
all other isolates had 89% similarity to the N. meningitidis porA.
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non-recombinant pseudogenome alignments for each dataset through RAxML v8.2.12
(Sommer et al., 2017). Pairwise phylogenetic distances were calculated after removal of predicted
recombinant regions using the ape package in R. Phylogenetic distributions of genetic resistance
variants were assessed by estimating the phylogenetic D statistic (Fritz and Purvis, 2010) using the
caper package in R. Bayesian analysis of population structure was performed on the pseudogenome
alignments for each dataset using fastBAPS (Tonkin-Hill et al., 2019). Multilocus sequence types
(MLSTs) were assigned using the PubMLST database (https://pubmlst.org/neisseria/).
Sampling approaches
For each sampling approach/dataset/variant combination, 100 simulations were carried out with iso-
late sampling continuing until variant detection. We defined ‘detection efficiency’ as one minus the
fraction of isolates sampled prior to variant detection (excluding any samples for which the presence
or absence of the variant could not be determined). As detection efficiencies were not normally dis-
tributed, differential performance between random sampling and targeted sampling was assessed
by Mann Whitney U tests of differences in mean ranks of detection efficiencies. Because the purpose
of this study was to compare the rare variant detection efficiency between random sampling and tar-
geted sampling approaches, we did not evaluate RplD G70D in datasets 1 and 4 or for the penA
XXXIV allele in dataset 3, as the prevalence of these variants in these datasets was >10%.
In demography-aware sampling (datasets 1 and 2), the first isolate was selected at random, and
each successive isolate was randomly selected from alternating demographic groups (men vs.
women and men who have sex with men [MSM] vs. men who have sex with women [MSW] or women
who have sex with men [WSM]). For anatomical site (niche)-aware sampling (datasets 1 and 2), the
first isolate was selected at random, and each successive isolate was randomly selected from alter-
nating anatomical sites of isolate collection (i.e., cervix, urethra, rectum, and pharynx). For geogra-
phy-aware sampling (datasets 3 and 4), the first isolate was selected at random, and each successive
isolate was randomly selected from alternating geographic regions (countries or prefectures). For
geography- and distance-aware sampling (datasets 3 and 4), the first isolate was selected at random,
and each successive isolate was selected randomly from the region (country or prefecture) with the
largest product of geographic distances from previously sampled regions, only re-sampling from a
given region after all regions had been sampled in that round. For travel history- and sex work-aware
sampling (dataset 2), isolates were selected at random either limiting the pool to isolates from
patients who had recently engaged in overseas sex or sex work, respectively (Williamson et al.,
2019).
For phylogeny-aware sampling (datasets 1-5), the first isolate was selected at random, and each
successive isolate was either selected to maximize the product of phylogenetic distances from each
of the previously sampled isolates (“distance maximization”) or selected randomly with the excep-
tion of ensuring even sampling across phylogenetic groups (“clonal group”; i.e., isolates  N SNPs
from a previously sampled isolate that were excluded from future sampling until all “clonal groups”
had been sampled). SNP cutoffs tested for the clonal group approach included 1) 134 SNPs, the
lower 95% confidence interval of the mean SNP distance across datasets 1-5 between each isolate
with phenotypic cefixime resistance (CFX-R), azithromycin resistance (AZM-R), and/or ceftriaxone
reduced susceptibility (CRO-RS, >0.25 mg/mL, >1 mg/mL, and 0.12 mg/mL, respectively) and the
closest susceptible isolate, and 2) 422 SNPs, the lower 95% confidence interval of the mean SNP dis-
tance across datasets 1-5 between each isolate with the RplD G70D mutation, the 23S rRNA C2611T
mutation, and/or the penA XXXIV allele and the closest isolate without the resistance variant. The
clonal group sampling approach was further tested by alternating sampling across fastBAPS and
MLST groups.
For genomic background-aware sampling, isolates were selected at random either limiting the
pool to isolates with genotypic ciprofloxacin resistance (i.e., the GyrA S91F mutation) or to isolates
with a mutation at PorB G120 and/or PorB A121, which have been associated with a range of resis-
tance pathways in multiple classes of antibiotics (Mortimer and Grad, 2019). Genomic background-
aware sampling was assessed in detection of CRO-RS (datasets 1 and 3–5; dataset 2 had no CRO-RS
isolates) and CFX-R (datasets 1 and 3–4; datasets 2 and 5 had no CFX-RS isolates).
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